News

The certification will allow WuXi to carry out non-clinical laboratory studies with respect to the requirements of the Chinese Food and Drug Act and SFDA GLP regulations. The

The two products use a patented delivery system, which will provide Canadian hospitals and healthcare professionals safety and cost effectiveness, according to the company. The products will be

The patients who have been diagnosed with advanced or metastatic solid tumours, including pancreatic, lung and ovarian cancers that are refractory to standard therapy, or for which no

Accelr8 which develops instruments used for the detection of pathogenic microorganisms has selected Tucson as best meeting its needs for future growth plans. Accelr8 president and CEO Lawrence

Agomelatine, a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist, is approved for the treatment of major depressive disorder in Europe, Australia and in other countries. Nectid

The company considers launching Soltamox, the FDA-approved oral liquid formulation of tamoxifen citrate, a first-line therapy for the prevention and treatment of breast cancer, later in 2012. DARA

The Phase II Small Business Technology Transfer Research (STTR) grant which will support the next two years of research will focus on extending a systems biology-cheminformatics approach to

The company’s abbreviated new drug application (ANDA) may be delayed for up to six months following the agency’s decision. Watson has filed a suit after communicating with FDA

Renaissance with the acquisition of Denavir has established a new subsidiary, Prestium Pharma (Prestium), to commercialize branded products in the US. Denavir is a topical antiviral used to